^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    metformin

    Company:
    Generic mfg.
    Drug class:
    AMPK activator
    Related drugs:
    1d
    Drug repurposing strategy to identify the putative leads against the Epidermal growth factor receptor (EGFR) from the USFDA-approved drug pool: Investigating the utility as an anticancer agent. (PubMed, J Mol Graph Model)
    The initial HTVS (high-throughput virtual screening), followed by XP analysis and molecular mechanics (MMGBSA) and ADME profiling, led to the identification of Cycloguanil (antimalarial) and Metformin (antidiabetic) as the putative lead molecules with the potential to inhibit the EGFR...Cycloguanil inhibited the EGFR with a half maximal inhibitory concentration (IC50) of IC50 of 490 nM compared to erlotinib with an IC50 of 222 nM...From the analysis, it was deduced that cycloguanil exhibited the most potent cytotoxicity towards the A549 cell with an IC50 of 6.83 μM, followed by HCT-116 with an IC50 of 9.32 μM, while in MCF-7, it exhibited an IC50 of 14.82 μM. The lead molecule, cycloguanil, may plausibly serve as an important template that may be optimized by performing bioisosteric replacements, leading to a putative kinase inhibitor with a potent anticancer profile.
    FDA event • Journal
    |
    EGFR (Epidermal growth factor receptor) • ANXA5 (Annexin A5)
    |
    erlotinib • metformin
    1d
    Evaluation of the Chemo-preventive Effect of Combined Topical and Systemic Metformin on Oral Leukoplakia (clinicaltrials.gov)
    P2, N=34, Recruiting, Cairo University
    New P2 trial
    |
    metformin
    2d
    Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Dec 2026
    Trial completion date
    |
    gemcitabine • albumin-bound paclitaxel • metformin
    2d
    Evaluation of metformin's effect on 5-fluorouracil-induced cardiotoxicity through cellular protection. (PubMed, Daru)
    According to the present study results, metformin, through a reduction in oxidative stress, apoptosis, and mitochondrial malfunction, can have therapeutic potential in HCM cells toxicity induced by 5-FU.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
    |
    5-fluorouracil • metformin
    3d
    "FIBR-MET-PF": Fibrosis-Modulating Effects of Metformin and Pirfenidone in Oral Submucous Fibrosis (clinicaltrials.gov)
    P1/2, N=45, Completed, Ziauddin University | Recruiting --> Completed
    Trial completion
    |
    metformin
    3d
    Chidamide and Anlotinib act synergistically in Jurkat cells by inhibiting the Hippo signaling pathway. (PubMed, Biochem Biophys Rep)
    To overcome these limitations, we systematically evaluated the synergistic Combination effects of three drug candidates, OTX-015 (BET inhibitor), Metformin (metabolic regulator), and Anlotinib (multitargeted tyrosine kinase inhibitor), with Chidamide. Chidamide and Anlotinib synergistically inhibit Hippo signaling pathway, which reveals a novel "dual epigenetic kinase targeting" strategy for the treatment of T-ALL. Future studies should validate these findings in vivo and investigate the impact of the metabolic microenvironment on therapeutic efficacy.
    Journal
    |
    CTGF (Connective tissue growth factor)
    |
    Focus V (anlotinib) • Epidaza (chidamide) • birabresib (OTX015) • metformin
    5d
    MCI: The Effects of Some Antihyperglycemic Drugs on Cognitive Function and Risk of Depression of Diabetic Patients (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Beni-Suef University | Trial completion date: Jan 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    metformin
    5d
    BLC2001: An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer (clinicaltrials.gov)
    P2, N=239, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2026 --> Mar 2027
    Trial completion date
    |
    Balversa (erdafitinib) • metformin • midazolam hydrochloride
    6d
    Regulation of NRF2/HMOX-1/GPX4 Signaling Pathway by She Ethnic Medicine Shiliang Tea Inhibits Ferroptosis and Attenuates Non-alcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus: Clinical Application and Mechanistic Study (ChiCTR2500115857)
    P=N/A, N=70, Not yet recruiting, Lishui People's Hospital; Lishui People's Hospital
    New trial
    |
    metformin
    6d
    Effects of Retagliptin Phosphate on BMD and bone metabolism markers in elderly female patients with type 2 diabetes mellitus (ChiCTR2500114555)
    P=N/A, N=86, Not yet recruiting, The Fifth Affiliated Hospital of Sun Yat-sen University; The Fifth Affiliated Hospital of Sun Yat-sen University
    New trial
    |
    metformin
    6d
    Efficacy of Daidzein Capsules Combined with Metformin in Metformin Low-Response Patients (ChiCTR2500112897)
    P=N/A, N=20, Recruiting, Jiangsu Province Hospital on Integration of Chinese and Western Medicine; Jiangsu Province Hospital on Integration of Chinese and Western Medicine
    New trial
    |
    metformin
    6d
    Clinical study on the regulation of diabetes by metformin combined with sugarcane polyphenols (ChiCTR2500111645)
    P=N/A, N=80, Not yet recruiting, Hebei Province Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine; Hebei Province Cangzhou Hospital of Integrated Traditional Ch
    New trial
    |
    metformin